BSEBoard Meeting5d ago · 14 Nov 2026, 06:52 pm
Outcome of the Board Meeting dated 14th November 2026
Sandu Pharmaceuticals Ltd · 524703
✦ AI SummaryResults
Sandu Pharmaceuticals Ltd announced the outcome of its board meeting held on November 14, 2026, where it approved the unaudited financial results for the quarter and half-year ended September 30, 2026. The results showed a profit before tax of ₹12197, and the company's board of directors took on record the unaudited financial results and the limited review report issued by the statutory auditors.
Analysis Scores
Earnings Impact8/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk6/10
Liquidity Impact9/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Sandu Pharmaceuticals Ltd - 524703 - Board Meeting Outcome for Outcome Of The Board Meeting Dated 14Th November 2026
Attachments (1)
📄pdf
Download →
17504cde-4cd9-48a0-8fc2-57d615acc7be.pdf
View document text
4% __ SANDU PHARMACEUTICALS LIMITED
CIN:L24233GA1985PLC001587
SAP/DU
m Regd. Office: Plot Nos. 25, 26, 29 & 30, Pilerne Industrial Estate, Marra, Saligao, Bardez, Goa 403511.
Tel: +918 2407474 / 6715000, E-mail: sandupharma@sandu.in, Website: www.sandu.in
Ref: SPL/CORP-SEC/2026-27/BSE/510
Dated:14.11.2026
Bombay Stock Exchange Ltd,
Phirojshah Jeejobhoy Towers,
25t Floor, Dalal Street,
Mumbai 400 001
Manager-Department of Corporate affairs
Sir,
Sub: Outcome of the Board Meeting held on 14th November 2026 with Scrip Code
524703.
Ref: Regulations 30 of SEBI (Listing Obligations & Disclosure Requirements)
Regulations. 2015
A Meeting of the Board of Directors of the Company duly convened on Saturday, 14t
November 2026 at 04:00 p.m. and concluded at 6.40p.m. discussed the following
business:
Approval of Unaudited Financial Results for the quarter and half year ended 30h
September. 2026. The Unaudited Financial Results of the Company for the quarter and
half year ended 30th September 2026 prepared in compliance with Ind-AS and the
Limited Review Report issued by M/s Dave & Dave Chartered Accountants, Mumbai,
[Firm Registration. No. 102163W], Statutory Auditors of the Company pursuant to
Regulation 33 of Chapter IV of SEBI (Listing Obligations & Disclosure Requirements)
Regulations ,2015 have been reviewed by the Audit Committee and placed before the
Board of Directors of the Company in their meeting held today ON 14TH November 2026.
The same are approved and taken on record by the Board.
The Unaudited Financial Results for the quarter and half year ended 30th September
2026 and the Limited Review Report are also available in the website of the company at
www.sandu.in and are enclosed herewith for your kind perusal.
For Sandu Pharmaceuticals Limited
Pratika Mhambray
Company Secretary & Compliance Officer
ACS :36512
AN ISO 9001:2015 CERTIFIED ORGANISATION
Corporate Office: P. B. No. 17201, Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai - 400 071.
Tel.: +91 22 2528 4402 / 3306, E-mail: info@sandu.in
SANDU PHARMACEUTICALS LTD
Corporate Office: Sandu Nagar, D. K. Sandu Marg, Chembur, Mumbai ~ 400 071.
Tel: +9122 2528 4402 / 6920 4400, E-mail: info@sandu.in, Web:www.sandu.in
- - (Rsintabhs)
3 Months ended Half Yearly Year ended
Particulars Note No. e —
| 30th Sept 2026 | 30th June 2026 | 30th Sept 2025 | 30th Sept 2026 | 30th Sept 2025 "“z:::“"
| Unaudited | Unaudited | _Unaudited | Unaudited | Audited
[TINcomE
Revenue From Operations 1 194288 16388 3s8176) 23201 659305
Other Income 1 371 174 1044 656 4
Total income. 195159) 164051 3592.29] 3a38.58] 703739
EXPENSES 2 -
Cost of materialy cansurmed g 2 15908 391 135.94) 110118
Purchaof sSteocsk. in-Trade 2 s \ . 98547 4659 1648.07]
| coanges in inventories offiished goods,tockin - 2
Trade and workin-progress 2259 . 2026 333.09 40735
Employee benefits expense z 2013 51957 530,15 106908
Finance costs u 260 5.59) 525 112
Depreciation and amortiation expense 3 1655 1637 1657 3292 3453 7.9
Other expenses s o911 5L 57942 133089 1047.35 usucl
Total xpenses 18656 160457 347024 LR GaxL|
Profi/(loss) before exceptional tems and tax 8591 3605 714 12197] 10532 26554
Exceptionaiems/ Prior Period Adustment 00
| pRoFT/1L05S) BEFORE TAX w531] 605, 718 217 10532 g|
fres %
Carrent tax 204 5.7 2971 2977| 2939 s
Deferred tar 10y 354 54 pit 117 104
Short/ (Excess ax Provision 0o oo 0 1l ) o0 Y
| eror (oss) FoR THe PeRioD 853 na 5243 10138 7478 51|
OTHER COMPREHENSIVE INCOME
terms that wili o be recassified o proft o oss in
Subseauent periods
[kemeasurement gains/(osses) on post employment defned]
lbenefit pans ) 0 oo :] u:l
e ) et !
income tax relatng to tems that wil not be recassified to
profitorloss 203 23 224 a9 15 1638
‘TOTAL OTHER COMPREHENSIVE INCOME FOR THE
PERIOD (NET OF TAX) 1370 1552 1348 . 22|
TOTAL COMPRIENCOHME EFORN THSE PEIRIOVD (ENET|
OF TAX) 9223 38.35] 631 24295
Paid p Equity Capital 966.10] 966.10) %6619 965.10] 966.19)
(Face Value of Rs 10/- Per 3har)€ il
EARNINGPESR EQUITY SHARE ”
Basc os 037, osa 108 o7 18
Oluted 081 037, o84, 105] 077, 183/
For Sandu Pharmaceuticals Lt
Dated: 24th Nov 2026 DIN:- 10245195
flegd, Offa & Factry. PoiNos. 25,26, 29 & 30, Pl Industal Estaté Pllame, Marr, Saliao, Bardez Goa - 403511,
Tl 491 832 6715000/ 05 /36 / 2407475, E-masla ndupharma@sandiuin c
3 | CIN:L24233GA1985PLCOD1SET i ] 3 c
3~ _ SANDU PHARMACEUTICALS LTD
SANDU Corporate offco: Sandu Nagar, 0. K. Sandu Marg, Chembur, Mumbai ~ 400 071.
Tasres Tel.: +91 22 2526 4402 / 6920 4400, E-mal: Info@sandu.in, Web: www.sanduin
SPAHNDAU RAMACEUTICLIAMILTESD.
Standalone Bulance Sheet as at 30th Sept, 2026
B (Rs in lakhs)
i As at 30th Sept 2026 As at 31st March,
PARTICULARS a2
Amount () Amount ()
ASSETS
Non-current assets
Property, Plant and Equipment 848.22} 868.47)
Right of use assets 930.35) 942.13|
Capital Work in Progress 10.91f 6.41)
Other Intangible Assets 1.85] 1.86
Financial Assets
Investments 124231 1229.80|
Other Financial Asset 00| 3.08)
Other Non-Current Assets -~ 12,44 3.24|
3046.09| © 3054.99|
Current assets.
Inventories - 1133.48] 1047.13]
Financial Assets
Trade receivables 783.04) 541.09]
Cash and cash equivalents 314.27| 590.77|
Bank balances other than 9 (a) above. 83.72] 94.82)
Other current assets 357.08] 258.11f
2671.59) 2531.94)
5717.57 5586.93|
EQUITY AND LIABILITIES
Equity =
Equity Share capital 966.10| 966.10|
Other Equity 3435.20| 3401.23|
4401.30| 4367.33|
Non-current liabilities
Financial Liabilities
Finance Lease obligations 30.86| 30.95)
Deferred tax liabilities (Net) 141.63| 146.44]
172.49| 177.39,
Current liabilities
Financial Liabilities
Finance Lease obligations 6.43)
Trade payables Due to : 24
Micro and Small Enterprises 60.26) 61.72]
Other than Miero and Small Enterprises 478.27| 385.03
Otber Financial Liabilities 39.75) 31.27|
Other current liabilities 132.07| 206.59
Pro 42713 346.63)
1143.88| 1042.21
5717.67] 5586.93
For Sandu Pharmaceuticals Ltd
Balram Viswanathan
Place - Mumbal Managing Director
Dated : 14th Nov 2026 -, DIN :- 10245195
1 Regd. Offce & Factory : Pot Nos. 25, 25, 29 & 30, Pheme Industnal Estate, Pllema, Mama, Salgao, Bardez, Goa- 40351| fi“
] Tel: +91 832 671505/036 0/ 240074/75, E-mak: sandupharma@sandu.in !
CIlkL24239GA1935PLE001567
3~ SANDU PHARMACEUTICALS LTD
SAs I ‘/DU Corporate Office: Sandu Nagar, D. K. Sandu Marg, Ghembur, Mumb-a 40l0 071.
xvsren v avarveon Tel: +91 22 2528 4402/ 6920 4400, E-mall: info@sandu,in, Web: www.sanduin
SANDU PHARMACEUTICALS LIMITED
Standalone Statement of Cash Flow for the period ended 30th Sept, 2026
541 (RsIn lakhs)
“As a1 301h Sept 2026 As at 315t Mareh, 2026
Particulars.
Amoun(t) | Amoun(t§) | Amoun(t€ | Amown(t)
A, Cash flow from operating activities
Net Profit/ (Loss) before extraordinary itoms and tax il Gaicn
Adjustments for:
Dopreciation and amortisation expenses e H
Finance costs 559 1124
Interest income 1044 =
Otter Income
ol 7
AL los ls o wo an n cS eal e fo o rf d I on uv be is ft um l e dn et b ti sn /S eu xb ps ei cd ta er dy cS ra en did tu lP oh sy st eo sc -e u tt ri ac dea l rs e cP e iL vt ad b le 4000 4| b4
REq eu -i mt ey asI un rs etr mu em ne tn t gs a it nh sr /o lu og sh se O st ohe nr c C mo pm lp or ye eh ee dn es fi iv nee d I bn ec nom ie t plans o) : 5;1 1
32,10 1297
Operating profit/ (loss) before changes i operating assets & Habilities a4 08 2934
C (ih na cn eeg ae ses ) i !n d o ep ce rr eaa st ei n ig n a is ns ve ets n oris i 634 i eL
((i in nc cr re ea as se e) ) // d de ec cr re ea as se e i in n oT tr ha ed re o r pe ec re ai lv ia nb gl e ss s sefs - 12 005 8. 198 7)
Changes in operating liabilities
(increase) / decrease in Irade payables 91.77| 203
(increase) / decrease in other operating liabilities 15.99) 3274 1384 291.30)
Cash Generated from operation -178.67) Sie0
Income Tax Paid 2131 7498
Net Cash flow from Operating activites -209.98] 61158
B. Cash flow from investing activities
Purchases of Praperty, Plant and Equipment 539 7200
Proceeds from Matusity of Fixed Deposits placed with Banks 14.19] 70
[Showing first 8,000 characters — download PDF for full document]